Today, the U.S. Food and Drug Administration approved the use of ivacaftor (Kalydeco®) for children with cystic fibrosis ages 1 to 2 who have at least one mutation that is responsive to ivacaftor.
Site Search
Celtaxsys Inc. reported promising results today from an early stage clinical trial of a potential anti-inflammatory drug for people with cystic fibrosis.
Finding a Balance Between CF and High School
Growing up, I never had any doubts that I would one day go off to college and pursue a career, despite having cystic fibrosis. But when the time came to prepare to attend Marquette University and live on my own in Milwaukee, I knew I would need a plan in order to make my transition to college life as smooth as possible.
As a teacher with cystic fibrosis, I find it no surprise that heading back to school can be a shock to my system. But over the years, I've learned that if I can remember three main things, I can stay healthy through the transition back to school.
During my five months in Denmark for a study abroad program, I not only learned more about myself and others, but I became more confident in my ability to take care of myself. Don't let CF stand in the way of experiencing that, or any other dreams.
Ever wondered what it takes for a potential cystic fibrosis drug to become approved by the U.S. Food and Drug Administration? Here's an explanation of the four phases of clinical research.
Learn how Rachel Kinney manages her CF while away at college.
Earlier this month, we learned that the new CF drug Orkambi was approved by the FDA. This was such an exciting, memorable and emotional day for everyone in the CF community. We heard from many who were thrilled about the potential for this drug to help people with CF and also heard from those who would not benefit from this breakthrough. Following are some reactions from those this impacts the most: people with CF and their loved ones.